Anticipated 2023 Key Events: Projected growth of greater than20% in the company’s high-margin, recurring revenue stream from royalties to approximately $445 to $455 million driven by continued strength in Wave 2 products, including DARZALEX and Phesgo utilizing ENHANZE technology, as well as full year auto-injector royalty contribution. Two ENHANZE subcutaneous approvals and commercial launches by collaboration partners, including SC efgartigimod and SC atezolizumab. Four Phase 3 study data readouts from products utilizing ENHANZE by the company’s collaboration partners: SC efgartigimod in CIDP, ITP and Pemphigus; SC ocrelizumab for certain patients with multiple sclerosis. At least 2 new products utilizing ENHANZE entering Phase 1 development by the company’s collaboration partners. At least one new collaboration and licensing agreement for ENHANZE, for a partner to test our developmental large volume auto-injector plus ENHANZE(R), and for our small volume auto-injector. Initiation of a clinical study to continue to evaluate the feasibility testing of our large volume auto-injector. Up to $150 million in share repurchases, dependent on market conditions and other factors, as part of the $750 million three-year share repurchase plan authorized by Halozyme’s board of directors in December 2021 demonstrating the company’s continued commitment to a balanced capital allocation strategy.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HALO:
